Logo

ReiThera Reports First Patient Dosing with its COVID-19 Vaccine Candidate in Italy

Share this

ReiThera Reports First Patient Dosing with its COVID-19 Vaccine Candidate in Italy

Shots:

  • The first healthy volunteer has been dosed in a P-I study of GRAd-COV2 against COVID-19 which is conducted by the Lazzaro Spallanzani National Institute for Infectious Diseases under the sponsorship of ReiThera
  • The P-I study will evaluate the safety & immunogenicity of GRAd-COV2 in 90 healthy volunteers divided equally into two age cohorts: 18-55yrs. and 65-85yrs. with participants to be monitored over a 24wks. period. The P-I study will also evaluate vaccine dose for further investigation in a P-II/III trial
  • ReiThera is expecting the results of interim safety and immunogenicity analysis by mid Q4’20 which will guide dose selection for P-II/III trial. The company plans to commence international P-II/III in countries with high rates of SARS-CoV-2 infection by the end of 2020- post-P-I outcomes

­ Ref: PRNewswire | Image: Global Times

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions